Potential Therapeutic Options for COVID-19.

IF 2 Q3 INFECTIOUS DISEASES Infectious microbes & diseases Pub Date : 2020-07-16 eCollection Date: 2020-09-01 DOI:10.1097/IM9.0000000000000033
Xiaoqin Zheng, Lanjuan Li
{"title":"Potential Therapeutic Options for COVID-19.","authors":"Xiaoqin Zheng, Lanjuan Li","doi":"10.1097/IM9.0000000000000033","DOIUrl":null,"url":null,"abstract":"<p><p>The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.</p>","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"2 1","pages":"89-95"},"PeriodicalIF":2.0000,"publicationDate":"2020-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529694/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious microbes & diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/IM9.0000000000000033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19的潜在治疗方案
最近出现的冠状病毒病2019 (COVID-19)已迅速演变为一场大流行,感染人数超过1000万,死亡人数超过50万。目前还没有有效的治疗方法或疫苗来预防这种冠状病毒感染。在这篇综述中,我们根据以往关于严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)的研究信息,讨论了COVID-19的潜在治疗方案。人们正在努力发现新的COVID-19治疗剂,包括重新利用现有药物和开发专门针对sars -冠状病毒2 (SARS-CoV-2)或宿主因子的新药。通过对化合物文库的筛选,确定了利巴韦林、瑞德西韦、洛匹那韦/利托那韦和羟氯喹等不同类别的药物是抗COVID-19的潜在候选药物。针对sars -冠状病毒2的新型抗病毒药物正在开发中,其目标是病毒酶或功能蛋白,以及宿主因子或细胞信号通路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Effect of Retinoic Acid on Neutrophil Innate Immune Interactions With Cutaneous Bacterial Pathogens. Evaluation of 10 Different Pipelines for Bacterial Single-Nucleotide Variant Detection Prevalence of Depression in Elderly People Living with HIV: A Systematic Review and Meta-analysis Erysipeloid and Erysipelothrix rhusiopathiae Bacteremia Secondary to a Crab Stab Wound: A Case Report and Literature Review A Ten-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1